News

News

Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

13 October 2020

Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

23 September 2020

Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy

04 September 2019

Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited

28 March 2019

Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate

21 March 2019

关于TAEST16001注射液申报临床试验获得受理的公告

29 December 2018

Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals

15 October 2018

Athenex Announces Pipeline Expansion Initiatives in Conjunction with a Strategic Investment of $100 million by Perceptive Advisors

02 July 2018